Overview

Study of the Efficacy and Safety of MEDI4893

Status:
Completed

Trial end date:
2018-10-02

Target enrollment:

Participant gender:

Summary

Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

Phase:

Phase 2

Details

Lead Sponsor:

MedImmune LLC

Collaborators:

Antibacterial Resistance Leadership Group
Innovative Medicines Initiative and COMBACTE-NET
National Institute of Allergy and Infectious Diseases (NIAID)